Heba A. Hassan

发表

The Beta Marshall-Olkin Extended Uniform Distribution

Salah H. Abid, Heba A. Hassan, 2015 .

JNK signaling as a target for anticancer therapy

Heba A. Hassan, Heba A Hassan, Atsushi Narumi, 2021, Pharmacological Reports.

Design, synthesis, molecular docking and biological evaluation of novel 1,5-diarylpyrazole-N,O-dimethyl hydroxamate derivatives as antiproliferative agents.

Heba A. Hassan, Heba A Hassan, Adel A Marzouk, 2021, Journal of advanced Biomedical and Pharmaceutical Sciences.

STAT3 transcription factor as target for anti-cancer therapy

Heba A. Hassan, M. Abdel-Aziz, Heba A Hassan, 2020, Pharmacological Reports.

Recent updates of fluoroquinolones as antibacterial agents

Heba A. Hassan, S. Abbas, G. Abuo-Rahma, 2018, Archiv der Pharmazie.

Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations.

Heba A. Hassan, T. Kaoud, K. Dalby, 2017, Bioorganic chemistry.

New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization

Heba A. Hassan, S. Abbas, Hend A. A. Ezelarab, 2023, Molecular diversity.

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFRL858R/T790M Mutations

Heba A. Hassan, Heba A Hassan, Eman A M Beshr, 2022, Pharmaceuticals.

Structure-based design, synthesis and antiproliferative action of new quizoline-4-one/chalcone hybrids as EGFR inhibitors

Heba A. Hassan, M. Hisham, Heba A Hassan, 2022, Journal of Molecular Structure.

Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases.

Heba A. Hassan, M. Otsuka, A. Gouda, 2020, Bioorganic chemistry.

NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.

Heba A. Hassan, T. Kaoud, Chunli Yan, 2019, European journal of medicinal chemistry.

Design, synthesis, anticonvulsant activity, and pharmacophore study of new 1,5-diaryl-1H-1,2,4-triazole-3-carboxamide derivatives

Heba A. Hassan, Heba A Hassan, O. Aly, 2018, Medicinal Chemistry Research.

Rabi like angular splitting in Surface Plasmon Polariton - Exciton interaction in ATR configuration

Heba A. Hassan, H. Talaat, S. Negm, 2018 .

New quinoline/1,2,4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study

Heba A. Hassan, M. Otsuka, A. Gouda, 2021 .

Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia

Heba A. Hassan, S. Abbas, Hend A. A. Ezelarab, 2023, BMC Chemistry.

1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain.

Heba A. Hassan, H. Farag, G. E. Abuo-Rahma, 2009, Bioorganic & medicinal chemistry.

Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.

Heba A. Hassan, Heba A Hassan, M. Badr, 2022, Bioorganic chemistry.

Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.

Heba A. Hassan, Heba A Hassan, M. Badr, 2021, Bioorganic & medicinal chemistry.

Recent Perspectives of Anticancer Histone Deacetylase Inhibitors

Heba A. Hassan, Heba A Hassan, M. Mohamed, 2019 .

N‐Malonyl‐1,2‐dihydroisoquinoline as a Novel Carrier for Specific Delivery of Drugs to the Brain

Heba A. Hassan, Heba A Hassan, H. Farag, 2009, Archiv der Pharmazie.

NEUROPROTECTIVE EFFECT OF ADIOL AGAINST LITHIUM PILOCARPINE INDUCED-SEIZURES, BEHAVIRAL CHANGES AND COGNITIVE DEFICITESIN MALE MICE

Heba A. Hassan, M. Shehata, D. M. A. E. Motteleb, 2018, Zagazig University Medical Journal.

New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.

Heba A. Hassan, M. Montano, S. Abbas, 2019, Bioorganic chemistry.

Antibacterial and anticancer profiling of new benzocaine derivatives: Design, synthesis, and molecular mechanism of action

Heba A. Hassan, Reem K. Arafa, E. S. Nossier, 2022, Archiv der Pharmazie.

Immunomodulatory effect of new quinolone derivative against cisplatin/gamma radiation-induced renal and brain toxicity in mice.

Heba A. Hassan, Heba A Hassan, A. I. Nabeel, 2018, Journal of photochemistry and photobiology. B, Biology.

Design, synthesis, molecular docking, anti-Proteus mirabilis and urease inhibition of new fluoroquinolone carboxylic acid derivatives.

Heba A. Hassan, Heba A Hassan, R. A. Abd El-Baky, 2017, Bioorganic chemistry.

Design, synthesis, and biological investigation of quinoline/ciprofloxacin hybrids as antimicrobial and anti-proliferative agents

Heba A. Hassan, S. Abbas, Hend A. A. Ezelarab, 2022, Journal of the Iranian Chemical Society.

Development and Assessment of 1,5–Diarylpyrazole/Oxime Hybrids Targeting EGFR and JNK–2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation

Heba A. Hassan, Adel A Marzouk, Kamal S Abdelrahman, 2023, Molecules.

Novel antimicrobial ciprofloxacin-pyridinium quaternary ammonium salts with improved physicochemical properties and DNA gyrase inhibitory activity

Heba A. Hassan, S. Abbas, P. Kittakoop, 2021, Medicinal Chemistry Research.

New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.

Heba A. Hassan, S. Abbas, Hend A. A. Ezelarab, 2024, Bioorganic chemistry.

Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAFV600E: Design, Synthesis, and Antiproliferative Activity

Heba A. Hassan, A. Hayallah, L. H. Al-Wahaibi, 2023, Pharmaceuticals.

Design, synthesis, anticonvulsant activity, and pharmacophore study of new 1,5-diaryl-1H-1,2,4-triazole-3-carboxamide derivatives

Heba A. Hassan, O. Aly, Sameh M. Elnabtity, 2017, Medicinal Chemistry Research.